Sonja Schrepfer, MD, PhD, Sana Biotechnology, Seattle, WA, shares her highlights from the American Society for Cell & Gene Therapy (ASGCT) 24th Annual Meeting 2021. Recent developments include an improved focus and understanding of immunological barriers associated with allogeneic induced pluripotent stem cells (iPSCs) and chimeric antigen receptor (CAR) T-cells. Other highlights include advances seen in the development of iPSC-based therapies including iPSC-derived dopaminergic neurons for Parkinson’s disease and iPSC-derived retinal pigment epithelium (RPE) for macular degeneration. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.